0000000001205105

AUTHOR

Lucio Lo Coco

showing 45 related works from this author

PO-55 The persistence of residual vein thrombosis, after an episode of deep vein thrombosis, and the risk of new overt cancer

2007

medicine.medical_specialtybusiness.industryDeep veinCancerHematologymedicine.diseaseGastroenterologyThrombosisPersistence (computer science)Vein thrombosismedicine.anatomical_structureInternal medicinemedicinebusinessThrombosis Research
researchProduct

Il dosaggio biologico dei fattori della coagulazione e degli inbitori del fattore VIII

2006

researchProduct

Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis

2008

Context Patients with suspected deep vein thrombosis ( DVT) of the lower extremities are usually investigated with ultrasonography either by the proximal veins ( 2-point ultrasonography) or the entire deep vein system ( whole- leg ultrasonography). The latter approach is thought to be better based on its ability to detect isolated calf vein thrombosis; however, it requires skilled operators and is mainly available only during working hours. No randomized comparisons are yet available evaluating the relative values of these 2 strategies. Objective To assess if the 2 diagnostic strategies are equivalent for the management of symptomatic outpatients with suspected DVT of the lower extremities.…

Malemedicine.medical_specialtyDeep veinContext (language use)VeinsSettore MED/15 - Malattie Del Sanguelaw.inventionFibrin Fibrinogen Degradation ProductsRandomized controlled triallawD-dimermedicineHumansProspective StudiesUltrasonography Doppler ColorProspective cohort studyAgedVenous ThrombosisFirst episodeLegbusiness.industrydeep vein thrombosiultrasonographyGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryVenous thrombosismedicine.anatomical_structureD-dimerFemaleRadiologybusinessJAMA
researchProduct

Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients

2005

Outpatient treatment of deep vein thrombosis (DVT) has become a common practice in uncomplicated patients. Few data are still present in patients with comorbidity (such as cancer) or concomitant symptomatic pulmonary embolism. Cancer patients with DVT are often excluded from home treatment because they have a higher risk of both bleeding and recurrent DVT. We tested the feasibility and safety of the Home Treatment (HT) program for acute DVT a PE in cancer patients. Patients were treated as outpatients unless they required admission for other medical problems, were actively bleeding or had pain that requires parenteral narcotics. Outpatient treatment was with low molecular weight heparin (LM…

AdultMalemedicine.medical_specialtymedicine.drug_classHome NursingDeep veinLow molecular weight heparinSelf Administration.Patient Education as TopicRecurrenceNeoplasmsmedicineHumansAgedAged 80 and overVenous Thrombosisbusiness.industryWarfarinCancerHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisComorbidityHome Care ServicesPulmonary embolismSurgeryHospitalizationVenous thrombosismedicine.anatomical_structureOncologyFeasibility StudiesPatient ComplianceFemaleWarfarinbusinessPulmonary Embolismmedicine.drugFollow-Up Studies
researchProduct

La sostenibilità ambientale del settore alberghiero - Il ruolo dei piani energetici regionali

2007

researchProduct

Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

2018

Abstract Cryopreservation for the long-term storage of platelets (PLTs) is a useful method to overcome the limits of platelet shortage. This is an in vitro prospective study to evaluate the count, viability, and function of buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at −80 °C with a modified Valeri method. PLTs were stored in 6% DMSO with a patented kit. Overall, 49 BC-PLTs from 245 healthy volunteer donors were prepared, cryopreserved, and analysed before and after 3, 6, and 9 months of storage. In flow cytometry, a statistically significant reduction in CD 42b (92.7 ± 4.29% at T0 vs. 23.6 ± 27.5% at T3…

Blood PlateletsCryopreservationmedicine.diagnostic_testChemistryIn vitro studyEconomic shortageHematologyBuffy coat030204 cardiovascular system & hematologyCryopreserved plateletThrombin generationCryopreservationIn vitroFlow cytometryAndrology03 medical and health sciences0302 clinical medicineViabilityBlood Buffy CoatHealthy volunteersmedicineHumansPlateletDMSO030215 immunologyTransfusion and Apheresis Science
researchProduct

THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND CARDIOVASCULAR DISEASE

2007

researchProduct

Cancer-Related Venous Thrombosis: Residual Vein Thrombosis Improves Screening for Occult Cancer.

2007

Abstract Background. Clinical advantages of extensive screening for occult cancer in patients with idiopathic Deep Vein Thrombosis (DVT) is still debated since this approach improves early detection of cancer but not cancer-related mortality. Recently, we have demonstrated that patients with Residual Vein Thrombosis (RVT), 3 months after DVT, have a high risk for cancer in the subsequent 2 years (Siragusa S et al. Blood2005;106(11):OC262). At the present it is unknown whether RVT assessment may be used to select patients, with idiopathic DVT, who require screening for occult cancer. Objective of the study. We conducted a prospective study evaluating whether a RVT-based screening for cancer …

First episodemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryDeep veinImmunologyCancerColonoscopySigmoidoscopyCell BiologyHematologymedicine.diseaseBiochemistrySurgeryVenous thrombosismedicine.anatomical_structureInternal medicineCohortmedicinebusinessProspective cohort studyBlood
researchProduct

The Persistance of Residual Vein Thrombosis, after an Episode of Deep Vein Thrombosis, and the Risk of New Overt Cancer and Cardiovascular Disease

2005

Background. We have recently demonstrated that the presence of Residual Vein Thrombosis (RVT), UltraSonography (US)-detected at the 3rd month after an episode of Deep Vein Thrombosis (DVT) of the lower limbs, is an independent risk factor for developing recurrent Venous Thromboembolism (VTE). The management of DVT patients by detection of RVT may, therefore, represent a simple and reproducible method for establishing the individual risk of recurrence and for tailoring the optimal duration of Oral Anticoagulants (OA) (Siragusa S et al. Blood 2003;102(11):OC183a). At the present, it is unknown whether RVT may also identify patients at increased risk for cancer and/or cardiovascular disease (C…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)Deep veinImmunologyCancerCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyThrombosisSurgeryVenous thrombosismedicine.anatomical_structureInternal medicinemedicinecardiovascular diseasesRisk factorProspective cohort studybusinessSurvival analysis
researchProduct

Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management

2007

medicine.medical_specialtyGastrointestinal bleedingbusiness.industryHematologyGeneral Medicinemedicine.diseaseGastroenterologySurgeryInternal medicinemedicineVon Willebrand diseaseIn patientAngiodysplasiabusinessGenetics (clinical)Haemophilia
researchProduct

Energy Conservation and Renewable Energy Use in the Tourist Sector: the Case Study of Sicily

2005

researchProduct

Successful treatment of acquired haemophilia with FEIBA and Retuximab

2005

researchProduct

Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis

2009

Abstract Abstract 3999 Poster Board III-935 Background Clinical advantage of extensive screening for occult cancer in patients with idiopathic Deep Vein Thrombosis (DVT) is unknown. We have demonstrated that the Residual Vein Thrombosis (RVT)-based screening for occult cancer improves early detection as well as cancer-related mortality (Siragusa S et al. Blood 2007;110(699):OC). Here we report on final analysis of 537 patients over a period of 8 years. Objective of the study We conducted a prospective study evaluating whether a RVT-based screening for cancer is sensitive and influences cancer-related mortality. Study design Prospective with two cohorts of DVT patients: the first cohort was …

First episodemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryDeep veinImmunologyCancerColonoscopyCell BiologyHematologymedicine.diseaseBiochemistryOccultSurgerycancer residual vein thrombosisSettore MED/15 - Malattie Del Sanguemedicine.anatomical_structureInternal medicineCohortCancer screeningmedicineProspective cohort studybusiness
researchProduct

Test di I livello nella diagnostica della malattia di Von Willebrand" in "Emocoagulazione ed Emostasi

2006

researchProduct

Objective Assessment of Pulmonary Embolism Can Be Deferred without Increased Risk

2005

Abstract Background. Management of patients with suspected Pulmonary Embolism (PE) is problematic if diagnostic imaging is not available. Pretest Clinical Probability (PCP) and D-dimer (D-d) assessment were shown to be useful to identify those high risk patients for whom empirical, protective anticoagulation is indicated (Siragusa S et al. Arch Intern Med2004;164:2477–82). Objective of the study. In consecutive patients with suspected PE, we evaluated whether PCP and D-d assessment, together with the use of low molecular weight heparins (LMWHs), allow objective appraisal of PE to be deferred for up to 72 hours. Methods. In case of deferment of diagnostic imaging for PE, patients identified …

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryVentilation/perfusion ratioConfidence intervalSurgeryPulmonary embolismObjective assessmentInternal medicineAntithromboticMedicinebusinessPerfusionVenous thromboembolismFibrinolytic agent
researchProduct

Cryopreserved platelets: from in vitro thrombin generation potential to in vivo safety

2015

Abstract Background: Cryopreservation of platelets (PLTs) at -80°C with dimethyl sulfoxide (DMSO) can extend their shelf life up to 2 years. Cryopreserved PLTs (CRY-PLTs) are reported to have a greater in vivo hemostatic effect than liquid-stored PLTs. Aims of this study were: i. to evaluate the thrombin generation potential of buffy coat derived cryopreserved PLTs (CRY- BC PLT) in comparison with fresh buffy coat derived platelets concentrates; ii. to determine the efficacy and safety of CRY-PLTs transfusion in hematological patients with severe thrombocytopenia. Materials and methods: BC PLTs were obtained from 5 buffy coats and pooled. The final PLTs concentrates were leukoreduced by fil…

medicine.diagnostic_testP-selectinbusiness.industryImmunologyCell BiologyHematologyBuffy coatBiochemistryThromboelastographyCryopreservationAndrologyTissue factorThrombinIn vivoImmunologymedicinethrombin generation cryopreserved platelets DMSOPlateletbusinessmedicine.drug
researchProduct

The persistence of residual vein thrombosis, after an episode of deep vein thrombosis, and the risk of new overt cancer.

2007

researchProduct

Successful treatment of gastrointestinal bleeding with recombinant factor VIIa after kidney transplantation in patients with pancytopenia.

2006

Abstract Hemostatic disorders can often complicate transplantation procedures. Moreover, antihemmorhagic drugs may not efficiently control bleeding that occurs in such cases. We report on a patient who underwent kidney transplantation complicated by bone marrow aplasia and gastric bleeding who was succesfully treated with recombinant activated FVII (Novoseven). In May 2005, a 53-year-old man affected by chronic renal insufficiency underwent kidney transplantation. At the beginning of June, laboratory tests showed progressive reduction in the blood cell count with anemia, granulocytopenia, and thrombocytopenia related to the development of marrow insufficiency. We commenced transfusion thera…

Malemedicine.medical_specialtyGastrointestinal bleedingAnemiaPancytopeniaFactor VIIa.MelenamedicineHumansKidney transplantationTransplantationbiologybusiness.industryMiddle Agedmedicine.diseasePancytopeniaKidney TransplantationRecombinant ProteinsSurgeryTransplantationRecombinant factor VIIabiology.proteinErythrocyte CountSurgeryTransfusion therapymedicine.symptombusinessGastrointestinal HemorrhageTransplantation proceedings
researchProduct

Cancer Patients Requiring Interruption of Long-Term Anticoagulant Therapy: The Use of Fixed Sub-Therapeutic Doses of Low-Molecular Weight Heparin

2011

Abstract Abstract 1244 Introduction. We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in cancer patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures (defined as major and non major surgery) or chemotherapy inducing platelets depletion. Methodology. Cancer patients were defined to be at high (atrial fibrillation [AF] with previous stroke, prosthetic mitralic valves and venous thromboembolism [VTE] lasting < 3months) or low risk of thrombosis (AF without previous stroke, VTE lasted > 3 months, and prosthetic aortic valves). They discontinued VKA 5 + 1days before surgery or chemotherapy; in those at low-risk f…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentImmunologyLow molecular weight heparinAtrial fibrillationCell BiologyHematologyHeparinmedicine.diseaseBiochemistryChemotherapy regimenThrombosisSurgeryAnesthesiaNadroparinMedicinebusinessStrokemedicine.drugBlood
researchProduct

The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with …

2006

Hyperhomocysteinemia is considered an independent risk factor for atherosclerosis, atherothrombosis and Venous ThromboEmbolism (VTE) [1], [2] and [3]. Normal total plasma homocysteine concentrations range from 5 to 15 μmol/L in the fasting state. Hyperhomocysteinemia is classified as moderate (homocysteine concentration, 15 to 30 μmol/L), intermediate (> 30 to 100 μmol/L), and severe (> 100 μmol/L) on the basis of concentrations measured during fasting. Although severe hyperhomocysteinemia is rare, mild hyperhomocysteinemia occurs in approximately 5% to 7% of the general population. In this case, patients are typically asymptomatic until the third or fourth decade of life when premature Cor…

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHyperhomocysteinemiaTime FactorsHomocysteinePopulationHyperhomocysteinemiaGastroenterologyAsymptomaticchemistry.chemical_compoundFolic AcidRecurrenceRisk FactorsInternal medicineMedicineHumansIn patientRisk factoreducationHomocysteineAgededucation.field_of_studybusiness.industrynutritional and metabolic diseasesHematologyMiddle Agedmedicine.diseaseB vitaminsEndocrinologyTreatment OutcomechemistryCardiovascular DiseasesVitamin B ComplexPlasma homocysteineFemalemedicine.symptombusinessThrombosis research
researchProduct

An empirical approach for ranking environmental and energy saving measures in the hotel sector

2009

The energy demand of the hotel sector of an Italian region is here utilized for hierarchizing, by means of an empirical method, efficient measures devoted to energy saving and reduction of CO2 emissions. Due to the large number of consumers present in the selected territorial area and the lack in detailed data, the energy demand assessment is here carried out by the analysis of a sample of representative consumers. A short set of indexes, referring to energy and environmental performances, are defined and calculated for different clusters of hotels, grouped on the basis of site characteristics, opening periods, number of beds, and building age. Such indexes are utilized to establish lists o…

Settore ING-IND/11 - Fisica Tecnica AmbientaleRenewable Energy Sustainability and the EnvironmentEnergy (esotericism)Energy and environmental policySample (statistics)Energy consumptionEnvironmental economicsEnergy conservationEnergy consumptionTourism sustainabilityEconomyRankingCO2 emissionSustainabilityBusinessScenarios comparisonTourismEfficient energy use
researchProduct

Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management

2008

angiodysplasia
researchProduct

Role and clinical importance of Helicobacter pylori infection in hemodialysis patients

2008

Dyspepsia is an extrarenal symptom frequently found in hemodialysed patients; it is due to chronic renal failure, and uremic gastritis is a specific associated condition in chronic renal failure (CRF). On the other hand, in the general population, Helicobacter pylori infection is an important dyspepsia-related risk factor; its close connections with gastro-duodenal pathology are already known, above all the peptic disease in a really exclusive way. By observation of a dyalitic group of patients, opportunely matched with a no CRF group, we evaluated CRF-associated uremia and Helicobacter pylori infection which could eventually interact causing symptoms and lesions. A statistical analysis of …

Settore MED/14 - NefrologiaSettore MED/18 - Chirurgia GeneraleHelicobacter pylori hemodialysis
researchProduct

Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review.

2012

MaleMutationHemoglobinuria ParoxysmalHumansMembrane ProteinsFemaleThrombosisReviewEPNSettore MED/15 - Malattie Del Sangue
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer

2012

Cancer-related disseminated intravascular coagulation (DIC) is a life-threatening condition for which no effective treatment is currently available. Protein C (PC), a modulator of coagulation as well as the inflammatory system, has been successfully tested (in its activated recombinant form [a-rPC]) in sepsis-related coagulopathy, but with an increased risk for major bleeding. Plasma-derived PC (pd-PC) is more suitable than a-rPC in patients at high risk from bleeding due to its self-limiting process. We carried out a single-arm study evaluating the role of pd-PC in adult cancer patients with overt DIC. Over a period of 3 years, we treated 19 patients with overt DIC and a PC plasma concentr…

AdultMalemedicine.medical_specialtyGastroenterologySettore MED/15 - Malattie Del SangueNeoplasmsInternal medicineCoagulopathymedicineHumansBlood Coagulationdisseminated intravascular coagulationSurvival analysisAgedAged 80 and overDisseminated intravascular coagulationHematologic Testsbusiness.industryPlasma derivedAnticoagulantsCancerHematologyMiddle Agedmedicine.diseaseSurvival AnalysisThrombosisSurgeryCoagulationFemalebusinessProtein CProtein Cmedicine.drugAmerican Journal of Hematology
researchProduct

Concentrazione Citochimica e Markers Coagulativi nel BAL e nel Siero di Pazienti con ALI Settici vs non-Settici

2008

researchProduct

Polycythemia Vera as a Predisposing Factor for Aortic Stenosis: Prevalence and Correlation with Blood Cells Count and Mutational Status

2008

Abstract The association between Polycythemia Vera (PV) and thrombosis is multi-factorial involving the complex interaction between activated leukocytes, platelets and endothelium. Recent reports have postulated that PV patients may over express adhesive molecules on red cell surface, likely by JAK2 mutation (Wautier M et al. Blood.2007;110(3):894–901). This process activates endothelium with production of vascular growth factors and other mechanisms leading to atherosclerosis. Aortic Stenosis (AS) is the commonest valvular heart disease in western countries; its pathogenesis is mainly related to a degenerative process sharing many characteristics with atherosclerosis. At the present is not…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyvalvular heart diseaseCell BiologyHematologyHematocritmedicine.diseaseBiochemistryThrombosisGastroenterologySurgeryStenosisPolycythemia veraDiabetes mellitusRelative riskInternal medicineHeart failuremedicinebusinessBlood
researchProduct

Lung Immune and Coagulative Host Response in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (aeocpd).

2008

researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients

2006

researchProduct

Functional In Vitro Studies Of Buffy Coat Pooled Platelets Cryopreserved In Dimethyl-Sulphoxide With a New System

2013

Abstract Introduction Cryopreservation for long term storage of platelets (PLTs) represents a clinical useful method for avoiding platelet shortage. Many studies have tried to define, in vitro and in vivo, the entity and weight of storage-related PLTs lesions with discordant results related to different methods. We have performed an in vitro prospective study to evaluate PLTs count, viability and function of buffy coat derived pooled platelet concentrates (BC-PLTs) treated with dimethyl-sulphoxide (DMSO) and cryopreserved at -80°C with an innovative patented system not requiring laminal flow hoods and external manipulations. Materials and methods Each BC-PLTs was obtained from 5 buffy coats…

medicine.diagnostic_testCryopreserved platelets DMSOImmunologyCell BiologyHematologyBuffy coatBiologyBiochemistryThromboelastographyCryopreservationAndrologyIn vivoHemostasisImmunologymedicinePlateletMean platelet volumeAnnexin A5
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Le contraddizioni del solare fotovoltaico. Il caso emblematico della Sicilia

2006

researchProduct

Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms

2005

Abstract Background. Prothrombin time is a benchmark for functional assessment in cirrhosis and Factor VII levels (FVII), crucial in determining the prothrombin time, are genetically determined. Methods. We have evaluated the prothrombin time, a number of haemostatic variables synthesised by the liver (FII, FV, FVII and activated FVII, AT and fibrinogen) and two polymorphisms of the FVII gene (5′F7 and 353R/Q) in: (a) patients with liver cirrhosis ( n  = 118), (b) patients with chronic hepatitis ( n  = 102) and (c) controls ( n  = 100). Results. By one-way analyses of variance, the prothrombin time and the mean levels of the FII, FV, FVIIc, FVIIa, and AT were statistically different between…

Liver Cirrhosismedicine.medical_specialtyCirrhosisGenotypeLiver CirrhosiFibrinogenChronic liver diseasechemistry.chemical_compoundhemic and lymphatic diseasesInternal medicineGenotypemedicineHumansAlleleAllele frequencyAllelesHepatitis ChronicProthrombin timeAllelePolymorphism GeneticHepatologyFactor VIImedicine.diagnostic_testbusiness.industryGastroenterologyFactor VIImedicine.diseaseEndocrinologychemistryCase-Control StudiesProthrombin TimebusinessCase-Control Studiemedicine.drugHuman
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up.

2001

Stroke incidence rates in the Mediterranean area are higher compared to northern European countries. In this study, we present the 8-year prospective data from a small rural Sicilian town. This population, consisting of 1351 subjects (622 males and 729 females), is homogeneous for ethnic background with traditional healthy dietary habits and shows low cholesterol mean levels. We found that the risk of stroke was significantly associated with the record of at least one previous neurological symptom (PNS), such as lack of strength, loss of vision or speech or possible drop attacks, and high hematocrit in males, and to high body mass index (BMI) and waist-hip ratio (WHR), diabetes, hypertensio…

AdultMaleRural Populationmedicine.medical_specialtySettore MED/09 - Medicina InternaEpidemiologyPopulationEthnic groupDiabetes ComplicationsLeukocyte CountPredictive Value of TestsDiabetes mellitusEpidemiologymedicineHumansRisk factoreducationStrokeeducation.field_of_studybusiness.industryPublic healthAge FactorsLeukocyteMiddle AgedCerebrovascular disordermedicine.diseaseSurgeryStrokeItalyFemaleRisk factorRural areaCardiology and Cardiovascular MedicinebusinessDemographyFollow-Up StudiesAtherosclerosis
researchProduct

Evaluation of patients with thrombotic stroke by methionine loading oral curve

2004

researchProduct

Il dosaggio dell'inibitore

2007

emostasi coagulazione cute
researchProduct

Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica

2004

researchProduct

2002

medicine.medical_specialtybusiness.industryAlternative medicinemedicineCoagulation (water treatment)Critical Care and Intensive Care MedicineBioinformaticsIntensive care medicinebusinessCritical Care
researchProduct

Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study

2009

Abstract Background. The optimal duration of Oral Anticoagulant Therapy (OAT) for Deep Vein Thrombosis (DVT) can be tailored by Residual Vein Thrombosis (RVT) (Siragusa S et al. Blood2003;102(11):OC183), a marker able to assess the individual risk for recurrent thrombosis. However, in patients with idiopathic DVT the safety of early interruption of OAT, because of absence of RVT, is still debated. Objective of the study. In the present study, we evaluated the safety of withholding OAT, in patients with idiopathic DVT and without RVT, three months after the index thrombotic episode. Study design. Prospective controlled study with two groups: patients without RVT stopped OAT after 3 months wh…

medicine.medical_specialtyDeep veinImmunologyPopulationThrombophiliaBiochemistrydeep vein thombosis anticoagulationSettore MED/15 - Malattie Del SanguemedicineVeineducationFirst episodeeducation.field_of_studyresidual vein thrombosisbusiness.industrydeep vein thrombosiCell BiologyHematologymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryPulmonary embolismVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM

2004

AIM: To evaluate the predictive role of hs-CRP and fibrinogen for cardio- and cerebrovascular events in a population of patients with type 2 diabetes. METHODS: We studied 156 patients with type 2 diabetes, mean age 66+10 years, and 156 sex and age matched control subjects. Patients underwent physical examination, EKG, measurement of body mass index and blood pressure. A blood sample was drawn to evaluate glycaemia, total and HDL/LDL cholesterol, triglycerides, high sensitive C-reactive protein (hs-CRP), fibrinogen. Finally, patients underwent an ecocolordoppler examination of the common carotid arteries until the bifurcation. In a follow-up of 5+/-1.2 years we evaluated the following events…

Malemedicine.medical_specialtyHeart diseasePopulationType 2 diabetesFibrinogenRisk FactorsInternal medicineDiabetes mellitusPrevalenceHumansMedicineMyocardial infarctioneducationAgededucation.field_of_studyChi-Square Distributionbiologybusiness.industryUnstable anginaC-reactive proteinFibrinogenAcute myocardial infarction C-reactive protein Diabetes mellitusmedicine.diseaseCerebrovascular DisordersC-Reactive ProteinEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesCase-Control Studiesbiology.proteinCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational Journal of Cardiology
researchProduct

Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy

2006

researchProduct

PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY

2007

researchProduct